title: [Synergism of antitumor activity of gemcitabine and dioxadet in mice with ascitic Ehrlich's tumor].
abstract: Antitumor activity of a new cytostatic drug combination of gemcitabine and dioxadet have been studied in 86 female SHR mice transplanted with 5 x 10(6) of ascitic Ehrlich's tumor cells each. All mice received a single injection of gemcitabine, dioxadet on combination 48 hams after tumor cells introduction. In first series, experimental animals received maximal tolerable dose of gemcitabine (25 mg/kg) and one half of dioxadet maximal tolerable dose (2.5 mg/kg). In the second series of experiments, the animals received 5 mg/kg of dioxadet along with the same gemcitabine dose. Effect of drugs was compared using the time to ascites detection, body weight increase, and survival time. Gemcitabine and dioxadet administered separately and in combination inhibited the growth of ascitic Ehrlich's tumor in the mice. In both series of experiments antineoplastic activity of gemcitabine and dioxadet combination was significantly higher in comparison to the control groups receiving these drugs separately. The highest antineoplastic activity of the gemcitabine and dioxadet combination was observed when the maximal tolerable doses of both drugs was applied. However, the tumor cells growth was also significantly inhibited in mice receiving half of dioxadet dose. Synergism of antitumor activity of gemcitabine and dioxadet was not accompanied by appreciable increase in toxicity.
authors.forename: D Kh
authors.initials: DKh
authors.lastname: Latipova
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: A N
authors.initials: AN
authors.lastname: Stukov
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Semiglazova
authors.forename: L V
authors.initials: LV
authors.lastname: Filatova
authors.forename: A A
authors.initials: AA
authors.lastname: Tarasenkova
authors.forename: S F
authors.initials: SF
authors.lastname: Vershinina
authors.forename: S A
authors.initials: SA
authors.lastname: Kon'kov
authors.forename: I M
authors.initials: IM
authors.lastname: Krylova
authors.forename: V G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: A V
authors.initials: AV
authors.lastname: Panchenko
authors.forename: Ia G
authors.initials: IaG
authors.lastname: Murazov
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004334:Drug Administration Schedule; D004357:Drug Synergism; D005260:Female; D020714:Maximum Tolerated Dose; D051379:Mice; D008815:Mice, Inbred Strains; D013997:Time Factors; D014227:Triazines / Q000008:administration & dosage / Q000494:pharmacology*; D015430:Weight Gain; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D014227:Triazines; D003841:Deoxycytidine; C040269:dioxadet; D000093542:Gemcitabine